Evofem Biosciences Inc. (EVFM)
OTC PINK OTC PINK Primary Summary
Evofem Biosciences Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JH Jeffrey Hung Morgan Stanley | 247.17 | $3,089.64 | $2.47 | -$3,087.17 | -99.92% |
Evofem Biosciences Inc. (EVFM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Evofem Biosciences Inc. ever had a stock split?
Evofem Biosciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | Saundra Pelletier CEO | OTC PINK Exchange | 30048L104 CUSIP |
| US Country | 32 Employees | - Last Dividend | 18 May 2023 Last Split | - IPO Date |
Overview
Evofem Biosciences, Inc. is a biopharmaceutical company dedicated to addressing unmet needs in women's sexual and reproductive health. With a focus on innovation and development, the company has introduced Phexxi, a non-hormonal vaginal gel designed for pregnancy prevention. Evofem Biosciences is also engaged in the development of products aimed at preventing sexually transmitted infections (STIs), including chlamydia and gonorrhea, as well as recurrent bacterial vaginosis. The company’s headquarters are located in San Diego, California, underscoring its commitment to leveraging cutting-edge science to empower women with safe and effective health care solutions.
Products and Services
- Phexxi
Phexxi is a revolutionary vaginal gel designed for the prevention of pregnancy. As a non-hormonal contraceptive option, it offers women an alternative to hormone-based methods, catering to those seeking control over their reproductive health without the side effects associated with hormones. Its unique mechanism of action provides immediate protection, making it a flexible and convenient choice for many women.
- EVO100
Currently in development, EVO100 aims to prevent the transmission of chlamydia and gonorrhea in women. This product represents Evofem Biosciences’ commitment to expanding its portfolio to include innovative solutions for preventing sexually transmitted infections (STIs). By addressing these common yet serious health concerns, EVO100 seeks to offer women more options for protecting their sexual health.
- EVO200
EVO200 is another promising product in Evofem Biosciences' pipeline, focused on the prevention of recurrent bacterial vaginosis. Given the recurring and often frustrating nature of bacterial vaginosis for many women, EVO200 is being developed to offer a reliable and efficient solution to managing this condition. By targeting the prevention of recurrences, EVO200 has the potential to significantly improve the quality of life for affected women.
